Ixazomib-Dexamethasone (Ixa-Dex) Vs Physician'S Choice (Pc) In Relapsed/Refractory (Rr) Primary Systemic Al Amyloidosis (Al) Patients (Pts) By Prior Proteasome Inhibitor (Pi) Exposure In The Phase Iii Tourmaline-Al1 Trial.

Efstathios Kastritis,Angela Dispenzieri,Ashutosh D. Wechalekar,Stefan O. Schönland,Kihyun Kim,Vaishali Sanchorawala,Heather Jolie Landau,Fiona Kwok,Kenshi Suzuki, Ray Comenzo,Giovanni Palladini,Deborah Berg,Guohui Liu,Arun Kumar,Douglas V. Faller,Giampaolo Merlini

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 8|浏览0

暂无评分

摘要

8546Background: The PI bortezomib is commonly used in first-line therapy of AL, but new therapies are needed that are tolerable in the context of multi-organ dysfunction and that, in RRAL, offer im...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要